Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -69.06% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-69.06%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.55%
median of 547 covered companies
CURRENT VS SECTOR MEDIAN
-74.61%
vs the sector median at left
Eikon Therapeutics, Inc. Common Stock
Market Cap
$418.49M
Return on Equity (ROE)
-69.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$408.34M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
Market Cap
$410.54M
Return on Equity (ROE)
-80.96%
TTM Avg
-47.93%
3Y Avg
-34.61%
5Y Avg
-20.56%
Market Cap
$427.39M
Return on Equity (ROE)
-70.24%
TTM Avg
-381.56%
3Y Avg
-217.03%
5Y Avg
-155.40%
Market Cap
$405.52M
Return on Equity (ROE)
-51.17%
TTM Avg
-29.16%
3Y Avg
-33.45%
5Y Avg
-16.04%
Market Cap
$406.69M
Return on Equity (ROE)
-43.14%
TTM Avg
2.19%
3Y Avg
15.11%
5Y Avg
15.11%
Market Cap
$403.52M
Return on Equity (ROE)
-37.05%
TTM Avg
-58.80%
3Y Avg
-40.96%
5Y Avg
-32.01%
Market Cap
$438.56M
Return on Equity (ROE)
-0.01%
TTM Avg
-61.70%
3Y Avg
-96.25%
5Y Avg
-81.28%
Market Cap
$438.10M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $418.49M | -69.06% | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $408.34M | -28.18% | -0.06% | 10.58% | 10.58% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | -80.96% | -47.93% | -34.61% | -20.56% |
| Editas Medicine, Inc. (EDIT)vs › | $427.39M | -70.24% | -381.56% | -217.03% | -155.40% |
| Neurogene Inc. (NGNE)vs › | $405.52M | -51.17% | -29.16% | -33.45% | -16.04% |
| Carlsmed, Inc. (CARL)vs › | $406.69M | -43.14% | 2.19% | 15.11% | 15.11% |
| Myriad Genetics, Inc. (MYGN)vs › | $403.52M | -37.05% | -58.80% | -40.96% | -32.01% |
| Assembly Biosciences, Inc. (ASMB)vs › | $438.56M | -0.01% | -61.70% | -96.25% | -81.28% |
| NeoGenomics, Inc. (NEO)vs › | $438.10M | -6.60% | -10.82% | -11.36% | -7.59% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $446.57M | -52.56% | -31.09% | -101.75% | -86.54% |
ROE
-69.1%
ROA
-41.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -69.06% |
